Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 18, 2019 08:00 ET | Source: Amarantus Bioscience Holdings, Inc.

Amarantus Announces Positive Pre-Clinical Data for MANF in Wolfram Syndrome Presented at the 79th Annual Scientific Sessions of the American Diabetes Association

NEW YORK, NY, June 18, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (the “Company,” or AMBS), a US-based JLABS-alumnus biotechnology holding...
June 13, 2019 08:42 ET | Source: Amarantus Bioscience Holdings, Inc.

Amarantus Announces Issuance of US Patent No. 10,195,251 Covering MANF Treatment of Wolfram's Syndrome, Retinitis Pigmentosa, and Glaucoma for Subsidiary MANF Therapeutics

New York, NY, June 13, 2019 (GLOBE NEWSWIRE) -- via NEWEDIAWIRE -- Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (the “Company,” or AMBS), a US-based JLABS-alumnus biotechnology holding...
June 04, 2019 13:39 ET | Source: Amarantus Bioscience Holdings, Inc.

Amarantus to Present at 9th Annual LD Micro Invitational Conference

New York, NY, June 04, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (the “Company,” or AMBS), a US-based JLABS-alumnus biotechnology holding...
May 31, 2019 11:01 ET | Source: Amarantus Bioscience Holdings, Inc.

Amarantus Releases Letter to Shareholders

New York, NY, May 31, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (the “Company,” or AMBS), a US-based JLABS-alumnus biotechnology holding...
May 28, 2019 09:30 ET | Source: Amarantus Bioscience Holdings, Inc.

Amarantus Engages Evolution Venture Partners to Evaluate Strategic Alternatives for Expansion into the Emerging Legal Hemp Industry

New York, NY, May 28, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (the “Company,” or AMBS), a US-based JLABS-alumnus biotechnology holding...
January 17, 2019 07:00 ET | Source: Amarantus Bioscience Holdings, Inc.

MANF Therapeutics Receives Notices of Allowance Covering MANF Use as Treatment for Parkinson's in Europe and Diabetes in Japan

New York, NY, Jan. 17, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- MANF Therapeutics, a wholly-owned subsidiary of Amarantus Bioscience Holdings, Inc. (OTCPK: AMBS) in pre-clinical development...
January 15, 2019 07:00 ET | Source: Amarantus Bioscience Holdings, Inc.

MANF Therapeutics Receives Notice of Allowance from US Patent & Trademark Office Covering the Use of MANF or CDNF as a Treatment for Glaucoma, Macular Degeneration and Retinitis Pigmentosa

New York, NY, Jan. 15, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- MANF Therapeutics, a wholly-owned subsidiary of Amarantus Bioscience Holdings, Inc. (OTCPK: AMBS) in pre-clinical development...
January 07, 2019 08:00 ET | Source: Amarantus Bioscience Holdings, Inc.

Amarantus Provides 2019 Roadmap

NEW YORK, Jan. 07, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (the "Company," or AMBS), a US-based, JLABS-alumnus biotechnology holding company...
November 28, 2018 07:55 ET | Source: Amarantus Bioscience Holdings, Inc.

Coeptis Pharma Enters into Agreement to Acquire Elto Pharma

NEW YORK and WEXFORD, Pa., Nov. 28, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Coeptis Pharmaceuticals, Inc., a diversified commercial biopharmaceutical company, today announced that it has entered...
July 20, 2018 08:17 ET | Source: Amarantus Bioscience Holdings, Inc.

Amarantus Provides Corporate Update

NEW YORK, July 20, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Amarantus Bioscience Holdings, Inc. (OTC Pink:AMBS) (the "Company," or AMBS), a US-based JLABS-alumnus biotechnology holding company...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right